Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZW49 in HER2-expressing Cancers
NCT03821233Phase 1Completed
- Sponsor
- Zymeworks Inc.
- Start
- Apr 2019
- Primary completion
- Sep 2024
- Modality
- Bispecific Antibodies, Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs)
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of zanidatamab zovodotin in breast cancer, gastroesophageal adenocarcinoma and Solid tumors, sponsored by Zymeworks Inc. Primary endpoints: Incidence of Dose-Limiting Toxicities up to 4 weeks, Incidence of Adverse Events up to 7 months and 3 more. Started Apr 2019; status: completed.
02
Drugs
zanidatamab zovodotin
03
Conditions
breast cancergastroesophageal adenocarcinomaSolid tumors
Beyond the preview
Go deeper on NCT03821233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03821233.